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Determination of serum visfatin level in patients with Behcet disease,
comparing with normal population
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ZH AGAHI1, MA NAZARINIA1
1Department of Internal Medicine, Division of Rheumatology, Shiraz University of
Medical Sciences, Shiraz, Iran, 2Department of Internal Medicine, Shiraz University
of Medical Sciences, Shiraz, Iran, 3Department of Immunology, Shiraz University of
Medical Sciences, Shiraz, Iran, 4Autoimmune Diseases Research Center, Shiraz
University of Medical Sciences, Shiraz, Iran
Background: Behcet’s disease is an inflammatory, systemic and chronic disorder with
unknown etiology affecting multiple systems of body (1). The cause is not clear but seems
to be multifactorial, including immune system dysfunction (humoral and cellular immune
defects), endothelial cell dysfunction and genetic predisposition (2). White adipose tissue
produces variety of proteins in the name of adipocytokines, with important roles in body
metabolism. One of these newly identified secreted adipocytokines is visfatin, which is
secreted by the visceral fat and its plasma level increases during the obesity. It has insulin-
mimetic effects in metabolism of cultured cells and activates the insulin receptor (3). Visfa-
tin stimulates inflammatory cells like monocytes and can induces increasing circulating level
of IL-6 in mice. It have been considered as a new proinflammatory adipocytokine (4). Previ-
ous studies have evaluated visfatin level in immunologic disorders like rheumatoid arthritis
and showed it was significantly higher in comparing to control subjects (4,5,6). There was
no evaluation in patients with behcet disease yet.
Objectives: We have evaluated visfatin level in patients with behcet disease finding inflam-
matory role of that in pathogenesis and clinical manifestations of behcet disease.
Methods: We have evaluated 40 patients with Behcet’s disease fulfilled the International
Study Group Criteria for the Diagnosis of Behc¸et’s Disease (ISG) and 40 healthy subjects
from healthy candidates referring to behcet clinic of Shiraz medical university as a referral
center for these patients in south Iran. Both groups have been matched for age, body mass
index (BMI) and sex. Visfatin was checked in both groups using ELISA Kit.
Results: There were no significant difference between cases and controls in mean concen-
tration of visfatin level (P = 0.61). Difference in the visfatin level between patients with
active and inactive manifestations of Behcet’s disease approximated to the significant levels
(6.13  3.20 and 4.25  2.73, respectively; P = 0.07).
Conclusion: In view of our study, we have concluded that visfatin levels may affect the
clinical manifestations of BD maybe as a proinfalmmatory marker in pathogenesis and
active manifestations of Behcet’s disease although more cases should be included in future
works.
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Serum melatonin levels in Behcet’ s disease patients with vascular
involvement
G KESKIN1, A INAL2, L OZıSıK1, R _ILIKCI2
1DYBEAH, Department of Internal Medicine and Immunology, Turkey, 2GATA,
Department of Immunology, Turkey
Background: Behcet’ s disease is a chronic systemic vasculitis characterized by oral apht-
hous ulcers, genital ulcers, ocular disease, skin lesions, vascular disease and neurological dis-
ease. It’s thought that infectious microorganisms, genetic factors and immune system
abnormalities play role in the pathogenesis of the disease.
Melatonin is synthesized from tryptophan in the pineal gland, retina, kidneys and the gas-
trointestinal system. In the recent years some studies have been reported about the role of
melatonin in the immune system and inflammatory diseases. It’s known that melatonin
increases the secretion of some cytokines and nitric oxide from the inflammatory cells. This
effect is with the Th-1 cytokine response.
In this study we investigated the levels of serum melatonin in Behcet’s disease (BD) patients
with vascular involvement and melatonin’s diurnal rhythm.
Patients and methods: In this study 21 BD patients with vascular involvement (nine
female, 12 male, mean age 26.4  5.2 years, mean disease duration 6.71  4.54 years) and
20 healthy controls (seven female, 13 male, mean age 26.8  5.2 years) were included.
Serum melatonin levels were measured by ELISA, in the morning and night.
Results: In the BD patients group the mean serum melatonin levels were 27, 4  10.9 at
night and 19.7  8.6 in the morning. In the healthy control group the mean serum melato-
nin levels were 53, 2  18, 2 at night and 20.3  14.2 in the morning.
There was no change in the diurnal rhythm of the melatonin in the BD patient group. Mel-
atonin secretion at night was found to be lower in the BD patient group than the healthy
control group and it was statically significant (P < 0.001). There was no statically significant
difference between the groups in the morning.
Discussion: It’s unclear how melatonin influences the immune responses. In some of the
studies it has been shown that there is a possible regulatory effect of melatonin and in
some others it has been shown that melatonin inhibits the immune response by anti-
inflammatory effect. BD is a chronic inflammatory disease. In this study we found that diur-
nal rhythm of the melatonin didn’t change in BD patients but the serum melatonin levels
at night were lower. These findings can be due to the effects of melatonin on the inhibition
of inflammatory responses.
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Clinical usefulness of HLA-B51 in patients with Behcet’s disease of
Korea
H RYU, HJ BAEK, HJ CHOI, KH LEE, MR SEO, SY KIM
Gachon University Gil Hospital, South Korea
Objectives: To investigate the usefulness of HLA B-51 and its relationship with the clinical
manifestations in patients with Behcet’s disease of Korea.
Methods: Medical records of patients who were visiting to our rheumatology clinic from
January 2011 to December 2011 were retrospectively reviewed. Total 103 patients with HLA
B51 examination, who had at least one of symptoms associated with Behcet’s disease, were
enrolled. Demographic data and clinical features of Behcet’s disease were collected. Behcet’s
disease was diagnosed according to International Criteria or criteria of International study
group for Behcet’s disease or Chang’s criteria.
Results: Seventy-eight among 103 patients (75.7%) were diagnosed as Behcet’s disease.
The sensitivity of HLA B-51 for Behcet’s disease diagnosis was 35.9% and the positive pre-
dictive value was 71.8%. The relative risk of HLA B-51 was 8.98 (95% CI = 3.33–24.20,
P < 0.0001). In the patients with Behcet’s disease, the ratio of female to male was 2:1 and
the mean age (SD) was 41.6  11.1 years. The age of symptom onset was
32.6  12.0 years and the disease duration was 11.0  8.8 years. There were no differences
of age and sex between HLA B-51 positive and negative group. The onset of symptoms tend
to develop earlier in the Behcet’s disease patients with HLA B-51 positive group (n = 28/78,
35.9%) than in the HLA B-51 negative group (n = 50/78, 64.1%, P = 0.047).The absence of
HLA B-51 was statistically significantly related with gastrointestinal symptoms (n = 16,
P = 0.006), especially in the subset of iliocecal ulcerations (n = 9, P = 0.023). There were
no differences in other clinical features such as oral/ genital ulcer, uveitis, skin lesion, arthri-
tis, vasculitis and nerve involvement.
Conclusion: The sensitivity and positive predictability of HLA B-51 for Behcet’s disease in
our cases were not high, but the absence of HLA B-51 was significantly associated with gas-
trointestinal ulceration features of patients. Clinicians should be awareness about the risk of
gastrointestinal involvement in Behcet’s disease patients without HLA B-51.
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The distinct expressions of interleukin-15 and interleukin-15 receptor
a in Behçet’s disease
J-Y CHOE, H LEE, JH KIM, S-K KIM
Division of Rheumatology, Department of Internal Medicine, Arthritis and
Autoimmunity Research Center, Catholic University of Daegu School of Medicine,
Daegu, Korea
Objective: Interleukin-15 (IL-15) is a pleotrophic cytokine that is involved in the patho-
genesis of diverse inflammatory rheumatic diseases. The aims of this study were to compare
serum IL-15 levels and expression of its receptor (IL-15Ra) in Behc¸et’s disease (BD) with
those in other rheumatic diseases, and to identify the relationship between serum IL-15 lev-
els and various clinical parameters in BD.
Methods: One hundred fifty-eight subjects consisting of 40 BD, 38 systemic lupus erythe-
matosus (SLE), 40 rheumatoid arthritis (RA), and 40 healthy controls were enrolled. Serum
IL-15 levels were measured using an enzyme-linked immunosorbent assay. The proportion
of IL-15Ra expression on each leukocyte subset was measured by flow cytometry. Erythro-
cyte sediment rate (ESR) and C-reactive protein (CRP) were measured for each enrolled
subject. The clinical activity index of BD was assessed for BD patients.
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Results: Serum IL-15 levels in BD patients are significantly higher than those of healthy
controls, SLE, and RA patients (P < 0.001, P < 0.001, and P < 0.001, respectively). Serum
IL-15 levels in BD were closely related with ESR (r = 0.405, P = 0.027), but not with CRP
or the clinical activity index of BD (P > 0.05 for both). Additionally, there was no difference
in serum IL-15 levels between active and inactive disease states in BD (P > 0.05). The pro-
portion of IL-15Ra expression on total leukocytes was much lower for all rheumatic dis-
eases, including BD, than in healthy controls (P < 0.01 for SLE, P < 0.01 for RA, and
P < 0.05 for BD).
Conclusion: IL-15 and IL-15Ra system may be involved in the inflammatory process and
pathogenesis of BD.
Key words: Behc¸et’s disease, interleukin-15, interleukin-15 receptor a, ESR.
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The retrospective review of 39 intestinal Behcet’s disease focusing on
the requirement for the immunosuppresive drugs other than
corticosteroid
Y KIMURA, A TAKEUCHI, A KURUMI, H KONO, H KIKUCHI
Teikyo University School of Medicine, Japan
Objective: To examine the demography, clinical characteristics, features of intestinal
lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently
followed at a university hospital in Tokyo especially focusing on the factors that correlated
with additional immunosuppresive therapies to corticosteroid.
Method: The records of 39 patients with intestinal Behcet’s disease were retrospectively
reviewed who were treated at the Teikyo University Hospital between August 1st, 2011 and
March 31th, 2012. We compared the well-controlled patients treated only with steroid or 5-
ASA/SASP, with the poorly-controlled patients who required additional immunosuppressive
drugs or anti-TNFa antibodies.
Results: The patients were consisted of 26 male and 13 female with the average age of
56.8  13.1 years old. The mean age at onset of Behcet’s disease was 35.5  11.2 years.
They developed the intestinal lesions at mean age 41.3  13.0 years. HLA-B51 or HLA-A26
were positive in 35.4% or 32.3%, respectively. Seventeen cases were complete Behchet’s and
22 were incomplete type. Almost all patients had oral ulcerations and skin lesions. Twenty
five cases had arthritis, seven had epididymitis. Vascular and central nervous system involve-
ments were seen in eight and two patients, respectively. The most frequent initial symptom
for intestinal Behcet’s was abdominal pain (22 cases). Other initial symptoms were melena/
bloody stool (16 cases) and diarrhea (nine cases), fever (five cases), dysphagia (two cases).
The intestinal lesions existed in various lesions of the gastrointestinal tract including esoph-
agus (three cases) and small intestine (four cases), ileo-cecal area (31 cases), ascending
colon (seven cases), transverse colon (three cases), descending colon (three cases), sigmoid
colon (two cases), rectum (five cases). They (28 cases) were treated with predonisolone of
the average 32.5 mg daily as the initial dosage. Thirty two patients were treated 5-ASA or
SASP. Fourteen cases were added with methotrexate, and three cases with cyclosporine. Inf-
liximab was administrated in six cases. In the patients who needed immunosuppressive
drugs or anti-TNFa antibodies other than steroids, we found the significantly higher HLA-
B51 positivity (42%) and higher CRP at the beginning of treatment (10.5  8.5 mg/dL). In
addition, the poorly responded patients with corticosteroid and sulfasalazopyridine showed
more frequent atypical intestinal lesions.
Conclusion: The restrospective review revealed that the requirement for the additional im-
munosuppresive therapies could have a linkage to the HLA-B51 in patietnts with intestinal
Bachet’s disease.
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Important results derived from our 50 year-experience on familial
Mediterranean fever
N DILSEN
Istanbul Faculty of Medicine, Turkey
Background: Familial Mediterranean Fever (FMF) is the first described one and prototype
of the auto inflammatory diseases. It is quite prevalent in Turkey. My interest in FMF was
started in 1960 and I have been involved deeply since then. We organized First Interna-
tional Symposium on FMF at Istanbul in1983.
Objectives: To present our most important results and conclusions obtained from our
long experience
Methods: Our cohort is consisted of 544 patients (male 306, female 238, M:F 1.28) diag-
nosed according to our criteria. In most of the patients the disease started at juvenile age.
With a few exceptions they had a recessive inheritance. Family history was obtained in 41%
of our cases.
Results: Peripheral arthritis is one of the cardinal manifestations and the most common
isolated initial symptom. Interestingly enough it does not usually coincide with the other
attack components. We described three cases of typical ankylosing spondylitis associated
with FMF in 1963 and since then we have observed many such cases. HLA-B27 was not
found to be associated .Additionally we have also had cases fulfilling the spondyloarthritis
criteria .Depending to these observations we proposed that FMF should be included into
the spondyloarthritides group of disorders. AA amyloidosis is an important component of
its pathology (11%).We have been using colchicine successfully as the drug of choice since
1962.Its prophylactic effect was found to be very successful on amyloidosis and 81.7% par-
ticularly on fever, abdominal pain and chest pain but less on arthritis.We also observed two
cases of Behcet disease in our cohort. We published our diagnostic criteria in 1997.We
believe that it is much simpler and practical than the others.
Conclusion: FMF is an important disease for the physicians of different disciplines in Tur-
key. During last 50 years we have obtained many important features and information and
became more capable in its early diagnosis and treatment.
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Frequent oral ulceration during early disease may predict a severe
disease course for men with Behçet’s syndrome
V HAMURYUDAN1, G HATEMI1, N SUT2, S UGURLU1, S YURDAKUL1,
H YAZICI1
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Objective: Mucocutaneous manifestations are common manifestations of Behc¸et’s syn-
drome (BS). Their numbers and recurrence rates can be highly variable between patients
but it is not known whether these differences influence the disease course of BS at the long-
term.
Methods: We recently showed that 43% of 91 male BS patients who had entered a 6 months
placebo controlled trial of thalidomide had to use immunosuppressives for any complications
during the post-trial period. This time, we evaluated only the 30 patients that made-up the
placebo arm and looked at the relation between the frequencies of mucocutaneous manifesta-
tions during the trial and the use of immunosuppressives during the post-trial period.
Results: Fifteen (50%) patients had received immunosuppresives for major complications
during the post-trial period. Patients receiving immunosuppressive treatment had signifi-
cantly younger age at the onset of BS than those who did not develop organ involvement
(24.5  5 versus 29.7  3.8 SD years; P = 0.003). The mean number of oral ulcers recorded
throughout the trial was significantly higher among patients using immunosuppressives
compared to those who did not (2.09  0.96 versus 1.43  0.8; P = 0.029). This signifi-
cance, however, disappeared when adjusted for age at onset of BS (P = 0.16). ROC curve
analysis showed a cut-off of more than nine ulcers during 6 months has a sensitivity of
86.7% and a specificity of 53% for the use of immunusuppressives. The mean numbers of
genital ulcers, follicular lesions and erythema nodosum did not differ between patients
regarding the use of immunosuppressives.
Conclusion: These findings on a limited number of patients suggest that frequent occur-
rence of oral ulceration during the initial years of the disease may predict the development
of organ involvement in men with BS.
Disclosure of Interest: None Declared
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Subclinical atherosclerosis and oxidized LDL levels in familial
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1Division Of Rheumatology, Department Of Internal Medicine, Cerrahpasa Medical
Faculty, University of Istanbul, Istanbul, Turkey, 2Department of Family Medicine,
Medical Faculty, University Of Cumhuriyet, Sivas, Turkey
Objectives: To investigate markers of carotid atherosclerosis and oxidized low density lipo-
protein (oxLDL) levels in patients with Familial Mediterranean Fever (FMF) who have no
risk factors for cardiovascular disease.
Methods: We studied 44 patients (25 F/19 M; mean age: 33.5  7.5) with FMF in attack
free period and gender and age matched 44 healthy subjects (25 F/ 19 M; mean age:
33.4  7.0). Exclusion criteria were clinical coronary artery disease, chronic renal disease,
diabetes mellitus, hypertension, history of myocardial infarction, angina pectoris or cerebro-
vascular disease, dyslipidemia, metabolic syndrome or active infection. Those who were in
postmenopausal status and using anti-lipid drugs were also excluded. We measured carotid
artery intima- media thickness (IMT) and investigated presence or absence of atherosclerotic
plaques in the carotids, using Doppler ultrasound. We also assessed serum lipid and OxLDL
levels.
Results: Mean disease duration of the FMF patients was 20  9 years. The mean carotid
IMT (C-IMT) did not differ between patients and controls (0.52  0.10 mm versus
0.53  0.06 mm, respectively, P = 0.709). None of the patients or controls had atheroscle-
rotic plaques. Total and LDL cholesterol levels were significantly lower among patients com-
pared to controls (total cholesterol: 157.07  34.18 versus 181.05  36.79, respectively,
P = 0.002; LDL cholesterol: 100.48  30.13 versus 126.25  34.05, respectively, P = 0.001).
Whereas OxLDL levels were significantly higher in FMF patients (337.48  438.56 ng/dL)
when compared to controls (156.19  383.24 ng/dL), (P = 0.044). There was no correla-
tion between CIMT and OxLDL levels among both patients (r = )0.156, P = 0.324) and
controls (r = )0.196, P = 0.246).
Conclusions: Our study supports further evidence for no increased atherosclerosis in FMF.
As previously shown patients with FMF have low cholesterol levels when compared to
healthy controls (1–2). On the other hand, increased OxLDL levels could be associated with
increased sub-clinic inflammation.
References: 1. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-
media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford)
2009;48(8):911–5.
2. Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterranean fever (FMF) patients
at increased risk for atherosclerosis? Impaired endothelial function and increased intima
media thickness are found in FMF. J Am Coll Cardiol 2006;48:2351–3.
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Characteristics, treatment and outcome of GI involvement in Behcet
syndrome (BS): experience in a dedicated center
I HATEMI1, G HATEMI2, Y ERZIN1, A FERHAT CELIK1, H YAZICI2
1Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey,
2Istanbul University Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey
Background: Controlled data regarding the treatment of gastrointestinal involvement of
BS is lacking and long term prognosis is not well known.
Objectives: To report the demographic and disease characteristics, type of involvement,
treatment modalities and outcome of BS patients with gastrointestinal involvement (GIBS).
Methods: We retrospectively reviewed the charts of all BS patients evaluated by gastroente-
rologists in our multidisciplinary BS clinic with a suspicion of gastrointestinal involve-
ment, and surveyed those with a diagnosis of GIBS. Patients were evalauted either in the
outpatient clinic or if not possible by phone calls to assess their outcome.
Results: There are more than 8000 recorded BS patients in our multidisciplinary outpa-
tient clinic. Sixty-nine of them had symptoms suggesting gastrointestinal involvement and
lesions on endoscopy. Among these, 18 patients had other reasons for their gastrointestinal
symptoms. The remaining 51 patients had GIBS (Table). Surgery had to be performed in
20/51 patients. The most commonly used drugs for initial management were azathioprine
2–2.5 mg/kg/day (n = 33) and 5 ASA compounds 3–4 g/day (n = 13). Remission was
observed and there were no relapses during a mean follow-up of 44.3  46.9 months in
22/33 (67%) patients who had initially been prescribed azathioprine (2.5 mg/kg) and dur-
ing 45.0  50.1 months in 9/13 (68%) patients who had been prescribed 5 ASA com-
pounds. Other than the 33 patients who used azathioprine as their initial treatment,
remission was also obtained with azathioprine in 3/4 patients who were resistant to 5 ASA
compounds. Among the 10 patients who had relatively severe symptoms and persistent
large ulcers despite at least 6 months of azathioprine treatment, endoscopic and symptom-
atic remission could be obtained with thalidomide in four patients, infliximab in four
patients and adalimumab in two patients. After a mean follow-up of 7.1  4.8 years (range
0.25–17 years), 42 (84%) patients were in remission and 14 (28%) of these were off treat-
ment. Four (8%) patients were still active, 3 (6%) patients had died due to non-GI releated
reasons and 2 (4%) were lost to follow-up.
Conclusions: Eighty-four per cent of patients with GIBS were in remission after a mean of
7 years of follow-up. Surgery was required in 40% of patients with GIBS. Five ASA com-
pounds or azathioprine provided remission and prevented relapses in two thirds of the
patients. The latter was also beneficial in some patients resistant to 5 ASA compounds.
Resistant and relapsing cases could be managed with thalidomide or TNF-alpha antagonists.
Patients with GI involvement of BS (n) 51
Men:women 27:24
Mean age  SD (years) 38.5  9.3
Mean age at diagnosis of GIBS  SD (years) 31.2  7.1
Oral ulcers 51/51
Genital ulcers 43/51 (86%)
Positive pathergy reaction 27/51 (54%)
Skin lesions 34/51 (68%)
Arthritis 17/51 (33%)
Uveitis 10/51 (20%)
Vascular involvement 6/51 (12%)
Neurologic involvement 5/51 (10%)
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Rheumatological feature of lipid disorders
I KHANJAR
HMC, Qatar
Background and Introduction: It’s well known that hyperlipidemia increase the risk of
CVD and CAD, so the tight control of it and recommendation to lower it is established to
reduced the incidences of those event & reduced morbidity as well as mortality.
But it’s little known about rheumatic manifestation of lipid disorders and related condi-
tions.
Objective: To look for more details and new rheumatic manifestation of dyslipidemia.
Methods: Peer review search of English published articles concern of rheumatic manifesta-
tion of lipids disorders focus on multcentric histiocytosis as well as drugs ….in dyslipide-
mia.
Results: In the last decade the application of this results not shown only validity to high
risk people and condition such as HTN, DM, obesity, but also money studies have been
shown the same morbidity related to CVD in SLE and RA, and no drought that necessary to
approach these disease as risk of CAD, however in the last few years the few articles has
been published showing the same in another inflammatory arthritis such As and PsA..
In the last two decades of using lipid lower drugs raised more data about some side effect
mainly myopathy and some new benefit indication such hyperurecimia which interested to
rheumatologist. But so far very few data added in rheumatic feature of hyperlipedemia, so
more little about multicentric reticulohistiocytosis (MCH) has added in eathiopathology
and treatment. In this review discussing the money aspect of rheumatic manifestation of
lipid disorders and new data of MCH rheumatological manifestation and its recent treat-
ment as well as some drugs used in dyslipidemia with benefit and side effect balance
Conclusion: Dyslipidemia is common complication and its treatment has some disadvan-
tages which physician should be aware, but also has some other advantages benefit treat-
ment in such condition, however new clear data of MCH has been recently raised with
highlight important issue for rheumatologist
References: 1. Arch Dermatol. 2008 144, Ann Rheum Dis 2002, Ann Rheum Dis 2005;64,
JEADV (2001)
2. ARCH DERMATOL/VOL 140, AUG 2004, eMedicine’s, Pathology Outline Dec 2009.
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Decrease of progressing chronic heart failure and rheumatic heart
disease by vaccination of patients against influenza
AN KALYAGIN
Irkutsk State Medical University, Municipal Hospital o 1, Irkutsk, Russia
Purpose: To estimate the opportunity of use of vaccination against influenza in order to
decrease a risk of progresing chronic heart failure (CHF) on the background of rheumatic
heart disease (RHD).
Methods: There have been examined 80 randomly selected patients with RHD, verified on
data of history, clinical signs and ECG, aged 49 (32–64) years. The criteria of including
were: presence of CHF, absence of activity of rheumatic process. The patients were divided
into two groups: 1 (main group) – patients with CHF on the background of RHD, vacci-
nated against influenza (n = 35) and 2 (control group) — not vaccinated patients (n = 45).
The vaccine Vacsigrippe was used, there were no any adverse reactions. The patients in the
groups were initially compared on age, sex, type of pathologies of valvules, smoking dura-
tion and smoker index. Standard therapy CHF was given to all the patients (including
inhibitors of ATF, beta-adreno-blockers, diuretic, spironolactone and digoxin). The time of
observation – 1 year. The data on the results was presented in the form of mediana, mini-
mum and maximum. Statistical processing included one-factor dispersion analysis, test Stu-
dent’s and v2.
Results: The frequency of respiratory infections in the patients of the 1st group has
decreased in 2.6 times (P = 0.021) as compared with the 2nd group, however in 11
(31.4%) of patients they have been registered (three cases of acute respiratory viral infec-
tion, six cases of pneumonia, two cases of aggravation of chronic bronchites). Respiratory
infections have been registered in four smokers of five ones. In the control group there have
been revealed 27 (60.0%) cases of respiratory infections (18 cases of acute respiratory virus
infection, seven cases of pneumonia, two cases of aggravation of chronic bronchites). Respi-
ratory infections have been registered in five smokers of seven ones. General frequency of
hospitalizations of the patients with CHF from the 1st group essentially has decreased as
compared with the 2nd group (decrease of relative risk = 2.2, P < 0.001). It is necessary to
mention that during the observation’s period there wasn’t registered any essential difference
in frequency of fatal outcome in both groups, though there was noted a tendency to mortal-
ity decrease in the 1st group. In comparing the indices of CHF it was defined that in the 1st
group functional class (P = 0.324) practically was not changed. In the 2nd group functional
class (P < 0.001) essentially increased.
Conclusion: Vaccinal prevention of influenza allows to influence effectively upon such risk
factor of progressing CHF in the patients with RHD as intercurrent infections of respiratory
tract and to achieve essential decrease of hospitalization frequency and lethality, as well.
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The estimate of risk of chronic heart failure decompensation in
patients with rheumatic heart disease
AN KALYAGIN
Irkutsk State Medical University, Municipal Clinical Hospital o1, Irkutsk, Russia
Purpose: The purpose of our investigation was to estimate the risk of decompensation
development of chronic heart failure (CHF) on the background of rheumatic heart disease
(RHD).
Methods: There have been examined 578 patients aged 25–72 years with verified RHD.
The criteria of including in the investigation were: presence of CHF on Flemingem’s criteria
and absence of activity of rheumatic process. The patients were divided into two groups: (i)
patients, who had compensated CHF (I-II functional class) – 428 (7.0%), and (ii) patients,
having decompensated CHF (III-IV functional class) – 150 (26.0%). The patients in the
groups were equal in type of pathology of valvules, sex and age. Estimation of expressive-
ness of CHF was conducted on the scale of Mareev (2000) and on the test of 6-min walk.
Every risk factor (RF) was carefully revealed. Relative risk (RR) was also calculated. Statistical
processing has been carried out on the Mack-Nimar’s criteria in programme package Statisti-
ca for Windows v. 6.0 (StatSoft, USA).
Results: Hereditary, which was complicated with presence of acute rheumatic fevers in rel-
atives, was reliably registered in 188 patients (32.5%) and prevailed in the group of patients
with decompensation (RR = 1.5, P = 0.001).
Anemia was revealed in 190 (32.9%) patients, mainly iron-deficiency anemia, that was
proved with data of tests (RR = 1.9, P < 0.001).
Heavy physical labor with duration no <5 years in the history was established in 96 patients
(16.6%) (RR = 2.2, P < 0.001). At the same time hypodynamia was the main risk factor of
CHF decompensation in patients with RHD (RR = 1.8, P < 0.001). Low level of life has
been revealed in 119 (20.6%) patients. This index was not significant for progressing CHF.
Apparently, risk factors are accumulated out of clear connection with this index. It was
established that smoking gives RR = 1.7 (P = 0.017), alcohol — RR = 2.4 (P = 0.037), salt
— RR = 1.7 (P = 0.007).
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Respiratory infections, such as influenza, pneumonia, aggravation of chronic bronchitis are
important risk factors of CHF decompensation, even single episode of respiratory infection
during a year may influence significantly upon disease decompensation. In total, respiratory
infections were registered in 179 (30.9%) patients (RR = 1.6, P = 0.001) before the primary
examination.
Conclusion: Thus, risk factors play significant role in the CHF decompensation develop-
ment in patients with RHD.
704028
Update on treatment of Behçet’s disease
MM EL-SHEIKH
King Khalid Hospital, Najran, Saudi Arabia
1. Behc¸et’s disease is an inflammatory multisystemic disorder characterized by recurrent oral
ulcers, genital ulcers and involvement of the cutaneous (erythema nodosum), ocular (ante-
rior or posterior uveitis), musculoskeletal, vascular (both arterial and venous vasculitis), gas-
trointestinal and central nervous (meningo-encephalitis) systems.
2. The choice of treatment of Behc¸et’s disease depends on the patient’s clinical manifesta-
tions.
3. Mucocutaneous lesions are treated with topical corticosteroids, tetracycline, colchicine,
dapsone, or thalidomide.
4. Arthritis is treated with non-steroidal anti-inflammatory drugs (NSAIDs), systemic ste-
roids and local corticosteroid injections. Colchicine, sulfasalazine and methotrexate are also
used.
5. Uveitis is treated with topical drops (i.e, both mydriatic and corticosteroid drops), sys-
temic corticosteroids, azathioprine, cyclosporine, chlorambucil, tacrolimus, or cyclophos-
phamide.
6. Central nervous system disease usually is treated with corticosteroids, chlorambucil, or
cyclophosphamide.
7. Gastrointestinal lesions usually are treated with corticosteroids, sulfasalazine, or thalido-
mide.
8. Interferon alpha-2a is useful in oral and genital ulcerations, as well as papulo-pustular
lesions, erythema nodosum, thrombophlebitis, articular symptoms and ocular disease.
Tumor necrosis factor alpha (TNF-alpha) antagonists, such as etanercept or infliximab have
been used in treating CNS vasculitis, colonic ulcerations, esophageal ulcerations, panuveitis,
mucocutaneous ulcers and polyarthritis
704088
Increasing roles of flight surgeons to check for rheumatic conditions
during their medical examinations of pilots
H ASLAN
Ministry of Health, Ankara, Turkey
Rheumatologic diseases and related syndromes are associated with a variety of immune
abnormalities, and testing for these alterations in the immune response may be useful for
diagnosis and management of person with these diseases.
In the last decades, accepting more women for military and civil flying duties and produc-
tion of airplanes which can fly long distance and high performance military aircraft’s at our
country have increased our flight surgeons responsibility for their duties.
Now, with this respect, we have to detect the abnormality at the right time and the right
place and do the right action.
As we all know, selecting right person to right job will bring the success for military and
civil missions. Maintain the safe air travel makes our responsibility higher too.
With the help of new technologic laboratory methods, early detection of rheumatic condi-
tions and risks related to them has being possible for us.
The history and physical examination remain the cornerstones in the evaluation of the mili-
tary or civil flying person with rheumatic and musculoskeletal symptoms. They provide the
clinical basis for further laboratory or radiological testing.
The goals of laboratory testing for rheumatic diseases during the flying medical examina-
tions will be summarized.
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